Wilex Ag

Other

Epigenomics Ag

Therawis Diagnostics Gmbh

Sysmex Corporation

Roche Diagnostics Gmbh

Sekisui Diagnostics LLC

Biomedica Diagnostics Inc.

Manfred Schmitt

Viktor Magdolen

Nadia Harbeck

Olaf G Wilhelm

Sabine Maier

Thomas Luther

Heinz Hoefler

John Foekens

John W Martens

Horst Kessler

Fabian Model

Ralf Lesche

Christoph Riemer

Thomas Koenig

Inko Nimmrich

Almuth Marx

Matthias Kotzsch

Nadja Harbeck

Heinrich Graeff

Marcus Koppitz

Hideki Ishihara

Dimo Dietrich

Ulrich Weidle

Tomoko Matsushima

Satoshi Nakayama

Thomas Hildmann

Ronald Kates

Oliver Hartmann

Peter Adorjan

Antje Kluth Lukas

Armin Schmitt

Sybille Albrecht

Wolfgang Hanke

Markus Bürgle

Tamas Rujan

Martin Mueller

Frederique Spyratos

Volkmar Mueller

Ina Schwope

Gunter Weiss

Bernd Muehlenweg

Achim Plum

Maxime P Look

Frank Noack

Henner Graeff

Markus B&uuml;rgle

Johannes Hartfiel

Bernhard K&ouml;nig

Marion Kiechle

Rudolf Napieralski

Emil Zitzelsberger

Rupert Langer

Ulrike Schwarz-Boeger

Serenella Eppenberger-Castori

Vincent Vuaroqueaux

Thomas König

Heinz Höfler

John Martens

Frédérique Spyratos

The present invention relates to methods for predicting the efficacy of anthracycline-based neo-adjuvant chemotherapy in triple-negative breast cancer. This is achieved by determining epigenetic changes within the PITX2 gene. Detection of the methylation state of Cp G sites in a genomic sequence of PITX2 allows an estimate of the response or failure of an individual breast cancer patient to neo-adjuvant therapy.

Methods for assessing the treatment response of TNBC patients to neo-adjuvant chemotherapy by analysing CpG methylation

The present invention relates to methods for predicting the outcome of anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of PITX2; TFF1 and PLAU. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods.

Markers for the prediction of outcome of anthracycline treatment

There is provided a method of judging a risk of cancer recurrence based on the activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and the expression levels of uPA and PAI-1 and a computer program.

Method of judging risk of cancer recurrence and computer program

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the disease free survival and/or response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.

Methods for the prognosis of breast cancer

This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.

Nucleic acids encoding a deletion variant of uPAR

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.

Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy

Methods for the detection and prognosis of breast tumors

The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.

Diagnostic and therapeutic use of antibodies against the urokinase receptor

A method for training a neural network in order to optimize the structure of the neural network includes identifying and eliminating synapses that have no significant influence on the curve of the risk function. First and second sending neurons are selected that are connected to the same receiving neuron by respective first and second synapses. It is assumed that there is a correlation of response signals from the first and second sending neurons to the same receiving neuron. The first synapse is interrupted and a weight of the second synapse is adapted in its place. The output signals of the changed neural network are compared with the output signals of the unchanged neural network. If the comparison result does not exceed a predetermined level, the first synapse is eliminated, thereby simplifying the structure of the neural network.

Method for training a neural network

The present invention concerns peptides as inhibitors of the binding of urokinase to the urokinase receptor. These peptides, which are preferably cyclic, are suitable as pharmaceutical agents for diseases that are mediated by urokinase and its receptor.

Inhibitors for urokinase receptor

Method of and apparatus for control of saftey valves

There is provided a tooth system for the static transmission of a torque between two machine components coaxially disposed in one another, e.g. a shaft and a hub, in which the tooth surfaces are straight and are designed with a very large pressure angle and with large tip and root fillet radii. The pressure angle of one component deviating slightly from that of the other component by half the torsion angle so as to overcome backlash. As a result, under load, the tooth surfaces abut over their entire surface. Also, the hubs can be produced with a smaller blanking indentation, in particular in the case of discs made of sheet metal, which increases the bearing capacity, and furthermore this can be done even more precisely, which results in an increase in centering precision and less noise generation during operation.

Tooth system for a shaft-hub connection

Spring-loaded safety valve for gases and vapor

Growing community of inventors

Munich, Germany

Manfred Schmitt